Effect of an in vitro fertilization program on serum CA 125, tumor-associated trypsin inhibitor, free β-subunit of human chorionic gonadotropin, and common α-subunit of glycoprotein hormones

Fertility and Sterility

Volumn 74, Issue 6, 2000, Pages 1125-1132

  Unkila Kallio, Leila ^a   Tiitinen, Aila ^a   Alfthan, Henrik ^a   Vuorela, Piia ^a   Stenman, Ulf Håkan ^a   Ylikorkala, Olavi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Assisted reproduction; Cancer; Cause of infertility; GnRH a; Gonadotropins; Pregnancy

Indexed keywords

APROTININ; CA 125 ANTIGEN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; GLYCOPROTEIN; HUMAN MENOPAUSAL GONADOTROPIN; NAFARELIN; NAFARELIN ACETATE; PROGESTERONE; UNCLASSIFIED DRUG; UROFOLLITROPIN;

ADULT; ALPHA CHAIN; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; REPRODUCTION;

ADULT; CA-125 ANTIGEN; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; ENDOMETRIOSIS; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; GLYCOPROTEIN HORMONES, ALPHA SUBUNIT; HUMANS; INFERTILITY, FEMALE; LUTEAL PHASE; MENSTRUAL CYCLE; OVARIAN FOLLICLE; PROGESTERONE; PROSPECTIVE STUDIES; REFERENCE VALUES; TRYPSIN INHIBITOR, KAZAL PANCREATIC;

EID: 0033636926     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)01580-6     Document Type: Article

References (47)

1. Adverse effects of fertility drugs
2. Transvaginal Doppler study of uterine artery blood flow in in vitro fertilization-embryo transfer cycles
3. Circulatory dysfunction in asymptomatic in vitro fertilization patients. Relationship with hyperestrogenemia and activity of endogenous vasodilators
4. Infertility, fertility drugs, and invasive ovarian cancer; a case-control study
5. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women
6. Risk of cancer after use of fertility drugs with in-vitro fertilisation
7. Characteristics relating to ovarian cancer risk; collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group
8. Ovarian tumors in a cohort of infertile women
9. CA 125; the past and the future
10. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring
11. Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125
12. Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome
13. Correlation between peripheral CA-125 levels and ovarian activity
14. Serum CA-125 levels do not depend on ovarian steroidogenesis
15. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA
16. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours; a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids
17. Biology and function of tumor-associated trypsin inhibitor, TATI
18. Human pancreatic secretory trypsin inhibitor. Distribution, actions and possible role in mucosal integrity and repair
19. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer
20. Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis
21. Pathophysiological importance of various molecular forms of human choriogonadotropin
22. Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms
23. Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer
24. Regulation of gonadotrophin subunit gene expression
25. Immunological evidence for the occurrence of luteinizing hormone-releasing factor and the alpha-subunit of glycoprotein hormones in carcinoid tumors
26. hCG and hCG subunits as tumour markers in patients with endocrine pancreatic tumours and carcinoids
27. Glycoprotein hormone alpha-subunit secretion in prolactinomas and in non-functioning adenomas; relation with the tumour size
28. Classification and staging of gynecologic malignancies. ACOG technical bulletin no. 155-May 1991
29. Choriogonadotropin and its beta subunit separated by hydrophobic-interaction chromatography and quantified in serum during pregnancy by time-resolved immunofluorometric assays
30. Disappearance of human chorionic gonadotropin and its alpha- and beta-subunits after term pregnancy
31. Serum CA 125 levels during the menstrual cycle
32. Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles
33. Use of a new CA 125 assay in the diagnosis of endometriosis
34. The performance of CA-125 measurement in the detection of endometriosis; a meta-analysis
35. CA 125 in serum, peritoneal fluid, active lesions, and endometrium of patients with endometriosis
36. CA 125 is an excretory product of human endometrial glands
37. Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle
38. Circulating CA-125 levels in superovulated women are mainly derived from the ovaries
39. Relationship between serum CA 125 levels, endometrial thickness and corpus luteum function in different stages of ovarian activity
40. Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies
41. Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty
42. Peripheral CA 125 levels in patients with uterine fibroids
43. Correlation of serum and follicular fluid concentrations of placental protein 14 and CA-125 in in vitro fertilization-embryo transfer patients
44. Evaluation of serum CA 125 concentrations as predictors of pregnancy with human in vitro fertilization
45. Tumour-associated antigens, CEA, CA 125 and SCC in serum and follicular fluid of stimulated and unstimulated cycles
46. CA-125 concentrations in the serum and pregnancy outcome in IVF cycles
47. Serum CA-125 values on the day of oocyte retrieval are not predictive of subsequent pregnancy with in-vitro fertilization